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Objective: The identification of sentinel lymph nodes (SLNs) near injection sites is 
difficult, due to scattered gamma rays. The purpose of this study was to investigate the 
optimal energy windows for elimination of scattered gamma rays, to improve the 
detection of SLNs. 
Methods: The clinical study group consisted of 56 female patients with breast cancer. 
While the energy was centred at 140 keV with a 20% window for Tc-99m, this energy 
window was divided into 5 sub-windows with every 4% in planar imaging. Regions of 
interest were placed on SLNs and background (BG), and contrast was calculated via a 
standard equation. The confidence levels of interpretations were evaluated using a 
5-grade scale. 
Results: The contrast provided by 145.6 keV ± 2% was the best, followed by 140 keV ± 
2%, 151.2 keV ± 2%, 134.4 keV ± 2%, and 128.8 keV ± 2% in that order. When 128.8 
keV ± 2% and 134.4 keV ± 2% were eliminated from 140 keV ± 10% (145.6 keV ± 6%), 
the contrast of SLNs improved significantly. The confidence levels of interpretation and 
detection rate provided by the planar images with 140 keV ± 10% were 4.74 ± 0.58 and 
3 
94.8% respectively, and those provided by 145.6 keV ± 6% were 4.94 ± 0.20 and 
100%. 
Conclusions: Because lower energy windows contain many scattered gamma rays, 
upper offset energy windows which exclude the lower energy windows improve the 
image contrast of SLNs near injection sites. 
 
Keywords: Sentinel lymph node, Energy window, Planar images, 













A sentinel lymph node (SLN) is defined as the lymph node that is first to 
receive lymphatic drainage from a tumour. When the SLN is tumor free, the nodal basin 
can be regarded as free of disease, and unnecessary dissection can be avoided [1]. Arm 
problems, such as numbness, pain, restricted arm mobility and lymphedema are 
influenced by the number of lymph nodes removed. Complications from axillary lymph 
node dissection may be reduced by limiting the extent of dissection using SLN biopsy 
[2, 3]. Preoperative detection of SLNs permits surgeons to locate nodes efficiently with 
a gamma probe during surgery, and lymphoscintigraphy can accurately reveal the 
localisations of SLNs in this context [4, 5]. One of the major problems in 
lymphoscintigraphy is the inclusion of scattered gamma rays within the photo-peak 
energy window. In Compton scattering, the energy of scattered gamma rays depends on 
the scatter angle (Fig. 1) [6]. Scattered gamma rays sometimes hamper the identification 
of SLNs near injection sites. Therefore, we hypothesised that optimal energy windows 
may eliminate scattered gamma rays, which could result in improved SLN detection. 
The purpose of this study was to investigate the optimal energy windows for elimination 





To evaluate the optimal energy window and the difference in collimator 
characteristics, the low-energy high-resolution (LEHR) collimator and the low-to 
medium-energy general-purpose (LMEGP) collimator, for SLN lymphoscintigraphy in 
breast cancer patients, we used both injection site phantoms and lymph node phantoms, 
to simulate injection sites and SLNs. Injection site phantoms were 2 cm in diameter and 
1 cm thick, and contained 40 MBq (1.1 mCi) of Tc-99m pertechnetate. Lymph node 
phantoms were 5 or 10 mm in diameter and 1 cm thick, and contained 1.6, 4.0, 25.0, 
and 400.0 kBq (0.04, 0.11, 0.68, or 10.80 kCi) of Tc-99m pertechnetate. A total of 8 
lymph node phantoms were aligned 3 and 6 cm from the centre of the injection site 
phantom, in both the horizontal direction and oblique direction. The energy was centred 
at 140, 143, 146, 149 and 152 keV, with a 15% window. Regions of interest were placed 
on SLNs and background (BG), and contrast was calculated with the following 
equation: Contrast = (SLN activity - BG activity) / (SLN activity + BG activity). 
Clinical study 
The study sample consisted of 56 consecutive female patients aged 56.1 ± 
13.1 years, with breast cancer that was histologically diagnosed between November 
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2013 and July 2014 inclusively. One patient was excluded because written informed 
consent was not obtained. The tumour was on the right side in 22 patients and the left 
side in 32, and was bilateral in 2 patients. A 37 MBq dose of Tc-99m phytate (Fujifilm 
RI Pharma, Japan) was injected subcutaneously around the tumour. Location markers 
containing 0.3 MBq (8.1μCi) of Tc-99m pertechnetate were placed at the centre of the 
sternal notch and the xiphoid process. Planar imaging was performed at 10 min and 3 - 
4 hours after injection. The injection sites were not covered with a lead shield. The 
counts in the planar image were collected for 6 min in a 256 × 256 matrix, with a low-to 
medium-energy general-purpose (LMEGP) collimator. While the energy was centred at 
140keV with a 20% window for Tc-99m, this energy window was divided into 5 
sub-windows with every 4% in planar imaging. The energy window was centred at 
128.8 keV ± 2%, 134.4 keV ± 2%, 140 keV ± 2%, 145.6 keV ± 2% and 151.2keV ± 2% 
without overlaps. A dual-head gamma camera equipped with a LMEGP collimator 
(Symbia T6; Siemens, Erlangen, Germany) was used for planar imaging. When the 
SLNs were not identified clearly, such as when the tumour was located in the upper 
lateral region, additional directional views were acquired. Five nuclear medicine 
physicians evaluated the planar images, and recorded their degrees of confidence in 
interpreting images with regard to the presence or absence of SLNs. The confidence 
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levels of interpretation were evaluated using a 5-grade scale: 1, definitely not identified; 
2, probably not identified; 3, equivocal; 4, probably identified; and 5, definitely 
identified. Detection rate was calculated as the number of patients whose average 
confidence levels of interpretation were more than 4, divided by the total number of 
patients. When the average confidence levels of interpretation were more than 4.6, the 
clinical interpretation was that the SLN had been definitely identified, and when it was 
less than 2.9 it was that it had not been identified. Average scores between 3.0 and 3.9 
were deemed equivocal, and scores between 4.0 and 4.5 were deemed to indicate that 
the SLN was probably identified. Confidence levels of interpretation were expressed as 
mean ± standard deviation (SD) and median. The confidence levels were compared 
using the Wilcoxon signed-rank test. Regions of interest were placed on SLNs and BG, 
and contrast was calculated with the following equation: Contrast = (SLN activity - BG 
activity) / (SLN activity + BG activity). Contrast and SLN counts were compared using 
the Student's t-test. Statistical significance was defined as p < 0.05. The study protocol 
was approved by the ethical committee of Kanazawa university hospital, and written 





Images derived from the phantom study are shown in Fig. 2. Lymph node 
and injection site phantom images were obtained with the LMEGP collimator (a - c) and 
the LEHR collimator (d, e). Lymph node phantoms contained 1.6, 4.0, 25.0, and 400.0 
kBq (0.04, 0.11, 0.68, and 10.80 μCi) of Tc-99m pertechnetate. Contrast was greatly 
affected by the radioactivity in the lymph nodes, and the distance from the injection site 
to the lymph nodes. Upper offset- energy windows showed better separation of SLNs 
from the injection site. Compared with the same radioactivity in lymph nodes and the 
same distance from the injection sites to the lymph nodes, image contrast was improved 
by using upper off-set energy windows (Table 1). Star-shaped artifacts radiating from 
the injection-site phantom occurred by using the LEHR collimator. Star-shaped artifacts 
were reduced using the LMEGP collimator. 
Clinical study 
The confidence level of interpretation and the detection rate provided by the 
planar images with 140 keV ± 10% were 4.74 ± 0.58 and 94.6% respectively. Average 
SLN counts and background for every 4% energy window are shown in Fig. 3. Lower 
energy windows contained many scattered gamma rays. The contrast provided by 145.6 
keV ± 2% was the best (0.743 ± 0.20), followed by 140 keV ± 2% (0.734 ± 0.20), 151.2 
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keV ± 2% (0.634 ± 0.26), 134.4 keV ± 2% (0.630 ± 0.23), and 128.8 keV ± 2% (0.409 ± 
0.24) (Fig. 4). The contrast provided by 140 keV ± 10% was 0.635 ± 0.22. The planar 
images generated with energy windows centred at 128.8 keV ± 2%, 134.4 keV ± 2%, 
140 keV ± 2%, 145.6 keV ± 2% and 151.2 keV ± 2% are shown in Fig. 5. When 128.8 
keV ± 2% and 134.4 keV ± 2% were eliminated from 140 keV ± 10% (145.6 keV ± 6%), 
the SLN contrast improved significantly, from 0.635 ± 0.22 to 0.730 ± 0.20 (p = 0.0063) 
and SLN counts decrease by approximately 42% compared with 140 keV ± 10% (Fig. 
6). Even when the 128.8 keV ± 2% count was eliminated from the 140 keV ± 10% 
count (142.8 keV ± 8%), the improvement in SLN contrast (from 0.635 ± 0.22 to 0.692 
± 0.21) was not significant, and SLN counts were reduced by approximately 13% 
compared with 140 keV ± 10% (Fig. 7). The confidence levels of interpretation and 
detection rate provided by the planar images with 145.6 keV ± 6% were 4.94 ± 0.20 and 
100% respectively. There was a significant difference between the confidence levels of 
interpretations associated with 140 keV ± 10% and 145.6 keV ± 6% (p < 0.0001). 
Relationships between SLN contrast and clinical interpretation, and between SLN 
counts and clinical interpretation are shown in Fig. 8. Clinical interpretations of SLNs 




Lymphoscintigraphy is a useful test for confirming the locations of SLNs 
preoperatively, making the biopsy of SLNs less invasive and ensuring that SLNs in 
unexpected locations are not missed. SLNs often appear only very faintly, because the 
radioactivity that flows into them is only a small proportion of the injected dose [7]. 
Due to the poor energy resolution of the NaI(Tl) scintillation crystal used in the imaging 
system (approximately 10% full width at half maximum, 140 keV) [8], the detection of 
some scattered gamma rays in the conventional photo-peak energy window is 
unavoidable. The reduced image quality is mainly due to Compton-scattered gamma 
rays contained in the preset energy window. Several techniques have been proposed for 
Compton scatter compensation [9-11]. 
Glass et al. [12] reported that adjustment of the energy window may improve 
the imaging of SLNs located close to injection sites. By acquiring only the high-energy 
component of the photo-peak, scattered gamma rays are reduced. Krynyckyi et al. [13] 
have shown that when the centre of the energy window was shifted upward by 5 keV, 
improved images with less background were obtained. Tsushima et al. [14, 15] reported 
that the contrast and detection capacity of lymphoscintigraphy were improved by using 
medium-energy collimator and an upper offset energy window of 146 keV ± 5%. 
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Since lower energy windows contain a significant amount of scattered 
gamma rays, the image contrast was reduced when including the lower energy windows, 
especially near injection sites. The detectability of SLNs was more affected by image 
contrast than SLN counts, when the SLNs were located close to injection sites. 
Although a few studies have investigated optimal energy windows for SLN imaging, 
none have compared conventional energy windows with optimal energy windows in a 
clinical setting. In our study, when an upper offset energy window, such as 145.6 keV ± 
6% (after subwindows of 128.8 keV ± 2% and 134.4 keV ± 2% were eliminated from 
140 keV ± 10%) was used for lymphoscintigraphy, the contrast was significantly 
improved. Although the SLN counts using 145.6 keV ± 6% were lower than those with 
140 keV ± 10%, upper offset energy windows yield better separation of SLNs from 
injection sites. However, aspect of the counts, and the contrast of the SLNs meant that 
the improvement was a trade-off issue. When the 5 offset energy windows without 
overlaps were used, we could adjust optimal energy windows depending on the situation 
after imaging. When SLNs are near the injection sites, planar images should be acquired 
with 145.6 keV ± 6%. We found that an image contrast of 0.5 and SLN count of 100 
yielded a suitable threshold level for interpretation of ‘definitely identified’ SLNs. A 
contrast value of 0.5 indicates that the SLN counts are 3 times greater than the 
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background counts. 
The information from lower energy windows may rule out artifact derived 
from injection sites. Although the photo-peak of Tc-99m occurred at approximately 141 
keV, scattered gamma rays might shift the peak to the lower energy side. The energy of 
Compton-scattered gamma rays is reduced, depending on their scattering angle. Our 5 
energy windows-based method could distinguish SLNs, and eventually reduced 
scattered gamma rays in planar images. When we eliminated some fractions of the 
lower energy windows, scattered gamma rays could be reduced while maintaining the 
primary gamma rays. 
Some studies have discussed the optimal collimator choice for planar 
imaging [15-19]. In most cases, SLNs that were not detected were located near injection 
sites. Collimator imaging with lower septal penetration is effective for the accurate 
identification of SLNs close to injection sites; lower septal penetration, such as LMEGP 
collimator, reduces the appearance of star-shaped artifacts from injection sites.  
The main variable parameter of the radio-pharmaceuticals used for SLN 
detection is particle size [4]. Phytate labelled with Tc-99m, which is mainly used for 
SLNs scintigraphy in Japan, forms a colloid in vivo upon reacting with ionised calcium. 
Tavares et al. [20] reported that a high rate (98%) of SLNs detection was achieved with 
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a gamma probe and SLN scintigraphy using Tc-99m phytate. In addition, if SLNs are 
not clearly detected in the initial planar imaging, massaging of stagnate injection sites is 
useful to enhance regional tracer flow. Multi-direction views are also helpful to detect 
SLNs when the tumours are located near axillary nodes that may be concealed behind 
injected radioactivity [21]. 
 
Conclusion 
Because lower energy windows contain many scattered gamma rays, upper 
offset energy windows which exclude lower energy windows improve the image 
contrast of SLNs near injection sites. In our phantom and clinical studies investigating 
optimal energy windows, 145.6 keV ± 6% was appropriate for SLN scintigraphy near 
injection sites. When the 5 offset energy windows without overlaps were used, we could 
derive an optimal energy window appropriate for the situation after imaging.  
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Legends for illustrations 
 
Table 1. Image contrast and counts from lymph node phantoms. The energy windows 
were centered 140 keV, 143 keV, 146 keV, 149 keV and 151 keV ± 7.5%. Lymph node 
phantoms contained 1.6 (1st row), 4.0 (2nd row), 25.0 (3rd row), and 400.0 kBq (4th row) 
of Tc-99m pertatechnetate. 
 
Fig. 1. Relationship between the energy of scattered gamma rays and their scatter angle, 
in Compton scattering. 
Fig. 2. Comparison of lymph nodes and injection site phantom images obtained with the 
low-to-medium-energy general purpose (LMEGP) collimator (a - c) and the low-energy 
high-resolution (LEHR) collimator (d, e). The energy windows were centred at 140 keV 
(a, d), 146 keV (b, e) and 151 keV (c) ± 7.5%. Lymph-node phantoms contained 1.6 (1st 
row), 4.0 (2nd row), 25.0 (3rd row), and 400.0 kBq (4th row) (0.04, 0.11, 0.68, and 10.80 
μCi) of Tc-99m pertechnetate. Injection site phantoms contained 40 MBq (1.1 mCi) of 
Tc-99m pertechnetate. These images were displayed different maximum scale, 
normalized to lymph-node phantoms counts. 
Fig. 3. The average SLN counts and background in planar images. 
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Fig. 4. Average SLN contrast obtained with 128.8 keV ± 2%, 134.4 keV ± 2%, 140 keV 
± 2%, 145.6keV ± 2% and 151.2 keV ± 2%.  
Fig. 5. Planar images of a 79-year-old female patient with breast cancer. Energy 
windows were centred at 128.8 keV ± 2% (a), 134.4 keV ± 2% (b), 140 keV ± 2% (c), 
145.6 keV ± 2% (d), 151.2 keV ± 2% (e), 140 keV ± 10% (f) and 145.6 keV ± 6% (g). 
Fig. 6. Planar images of a 67-year-old female patient with breast cancer. Energy 
windows were centred at 140 keV ± 10% (a) and 145.6 keV ± 6% (b). 
Fig. 7. Average contrast of SLNs obtained with 140 keV ± 10%, 145.6 keV ± 6% and 
142.8 keV ± 8%. 
Fig. 8. Relationship between SLN contrast and clinical interpretation (a). Relationship 
between SLN counts and clinical interpretation (b). 
 
Table 1  Image contrast (counts) of lymph node phantoms  
 
 






Distance from the injection site phantom to the lymph node phantom 
3 cm 6 cm 
The center of energy windows (±7.5%) 
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